Hill Street Beverage Company Inc. announced that it has signed a definitive agreement with Lexaria Bioscience to acquire the primary assets of Lexaria Canpharm, the sole licensee of the patents associated with the breakthrough DehydraTECH drug delivery process for use in products containing greater than 0.3% THC, commonly known otherwise as Cannabis 2.0 products. Lexaria's process has over 60 patents either issued or pending. The process provides for rapid onset and offset of the effects of cannabis, as well as provides the potential to create shelf stable products made from cannabis extracts. The Company is currently awaiting approval from The Toronto Stock Exchange to close the transaction. Hill Street has begun development of a facility in Mississauga where cannabis ingredients and consumer products will be manufactured. The Company expects the facility to be operational in 2021, pending Health Canada approval.